Emergent Biosolutions Inc (NYSE: EBS) has experienced a rise in its stock price by 8.88 compared to its previous closing price of 9.35. However, the company has seen a gain of 13.11% in its stock price over the last five trading days. globenewswire.com reported 2024-10-08 that GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emergent is working with businesses to prepare for accidental opioid emergencies by ensuring workplaces, facilities, and hospitality venues, among many other locations, should consider being equipped with NARCAN® Nasal Spray. In March 2024, Emergent joined the ‘White House Challenge to Save Lives from Overdose’, a nationwide call encouraging leaders to commit to increasing education of and access to life-saving opioid overdose reversal medications.
Is It Worth Investing in Emergent Biosolutions Inc (NYSE: EBS) Right Now?
EBS has 36-month beta value of 1.59. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EBS is 51.91M, and currently, short sellers hold a 15.85% ratio of that float. The average trading volume of EBS on October 22, 2024 was 2.81M shares.
EBS’s Market Performance
The stock of Emergent Biosolutions Inc (EBS) has seen a 13.11% increase in the past week, with a 55.42% rise in the past month, and a -18.49% fall in the past quarter. The volatility ratio for the week is 7.30%, and the volatility levels for the past 30 days are at 9.25% for EBS. The simple moving average for the past 20 days is 18.59% for EBS’s stock, with a 81.85% simple moving average for the past 200 days.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with Rodman & Renshaw repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to Rodman & Renshaw is $16 based on the research report published on August 22, 2024 of the current year 2024.
The Benchmark Company, on the other hand, stated in their research note that they expect to see EBS reach a price target of $5. The rating they have provided for EBS stocks is “Buy” according to the report published on March 07th, 2024.
EBS Trading at 22.01% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.58% of loss for the given period.
Volatility was left at 9.25%, however, over the last 30 days, the volatility rate increased by 7.30%, as shares surge +67.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.58% upper at present.
During the last 5 trading sessions, EBS rose by +13.11%, which changed the moving average for the period of 200-days by +331.36% in comparison to the 20-day moving average, which settled at $8.58. In addition, Emergent Biosolutions Inc saw 324.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from Zoon Kathryn C, who sale 10,000 shares at the price of $6.11 back on Jun 04 ’24. After this action, Zoon Kathryn C now owns 54,482 shares of Emergent Biosolutions Inc, valued at $61,100 using the latest closing price.
Zoon Kathryn C, the Director of Emergent Biosolutions Inc, sale 1,830 shares at $4.61 during a trade that took place back on May 29 ’24, which means that Zoon Kathryn C is holding 64,482 shares at $8,436 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.23 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.53. The total capital return value is set at -0.45. Equity return is now at value -87.44, with -31.80 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at 2.24. The interest coverage ratio of the stock is -4.49.
Currently, EBITDA for the company is -42.9 million with net debt to EBITDA at -9.65. When we switch over and look at the enterprise to sales, we see a ratio of 1.23. The receivables turnover for the company is 5.61for trailing twelve months and the total asset turnover is 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.06.
Conclusion
To put it simply, Emergent Biosolutions Inc (EBS) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
